Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Receivables - Net: 2022-2025

Historic Receivables - Net for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $465,104.

  • InMed Pharmaceuticals' Receivables - Net rose 20.64% to $343,469 in Q3 2025 from the same period last year, while for Sep 2025 it was $343,469, marking a year-over-year increase of 20.64%. This contributed to the annual value of $465,104 for FY2025, which is 31.82% up from last year.
  • According to the latest figures from FY2025, InMed Pharmaceuticals' Receivables - Net is $465,104, which was up 31.82% from $352,838 recorded in FY2024.
  • Over the past 5 years, InMed Pharmaceuticals' Receivables - Net peaked at $465,104 during FY2025, and registered a low of $66,775 during FY2023.
  • Moreover, its 3-year median value for Receivables - Net was $352,838 (2024), whereas its average is $294,906.
  • Per our database at Business Quant, InMed Pharmaceuticals' Receivables - Net dropped by 24.14% in 2023 and then surged by 428.40% in 2024.
  • Over the past 4 years, InMed Pharmaceuticals' Receivables - Net (Yearly) stood at $88,027 in 2022, then declined by 24.14% to $66,775 in 2023, then surged by 428.40% to $352,838 in 2024, then soared by 31.82% to $465,104 in 2025.